

Christof Bernemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/198595/publications.pdf>

Version: 2024-02-01

13
papers

255
citations

1306789

7
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

516
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 1-3.	0.9	113
2	Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. <i>Molecular Cancer</i> , 2014, 13, 174.	7.9	45
3	Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7645-7655.	4.6	23
4	Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3856-3864.	3.2	17
5	Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1921-1938.	1.1	13
6	Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods. <i>BJU International</i> , 2018, 122, 219-226.	1.3	11
7	Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. <i>J Clin Oncol</i> 2017;35:2149-56. <i>European Urology</i> , 2017, 72, e168-e169.	0.9	9
8	Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems. <i>World Journal of Urology</i> , 2017, 35, 1625-1627.	1.2	7
9	Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7 Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. <i>Eur Urol</i> 2017;71:4-6. <i>European Urology</i> , 2017, 71, 6-7.	0.9	5
10	Considerations for AR-V7 testing in clinical routine practice. <i>Annals of Translational Medicine</i> , 2019, 7, S378-S378.	0.7	4
11	Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
12	Reverse engineering of triple-negative breast cancer cells for targeted treatment. <i>Maturitas</i> , 2018, 108, 24-30.	1.0	3
13	Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. <i>Eur Urol</i> 2017;71:1-3. <i>European Urology</i> , 2017, 71, e107-e108.	0.9	1